pen-20260730

__________________________________________________________________________________________________________________________

UNITED STATES

SECURITIES AND EXCHANGE COMMISSION

Washington, D.C. 20549

_______________________________________________________________________________________________________________________________

FORM 8-K

_______________________________________________________________________________________________________________________________

CURRENT REPORT

Pursuant to Section 13 or 15(d) of the

Securities Exchange Act of 1934

July 30, 2026

Date of Report (Date of earliest event reported)

_______________________________________________________________________________________________________________________________

Penumbra, Inc.

(Exact name of registrant as specified in its charter)

_______________________________________________________________________________________________________________________________


Delaware	001-37557	05-0605598
(State or other jurisdiction of incorporation or organization)	(Commission File No.)	(I.R.S. employer identification number)

One Penumbra Place

Alameda, CA 94502

(Address of principal executive offices, including zip code)

(510) 748-3200

(Registrant’s telephone number, including area code)

Check the appropriate box below if the Form 8-K filing is intended to simultaneously satisfy the filing obligations of the registrant under any of the following provisions:


☐			Written communications pursuant to Rule 425 under the Securities Act (17 CFR 230.425)
☐			Soliciting material pursuant to Rule 14a-12 under the Exchange Act (17 CFR 240.14a-12)
☐			Pre-commencement communications pursuant to Rule 14d-2(b) under the Exchange Act (17 CFR 240.14d-2(b))
☐			Pre-commencement communications pursuant to Rule 13e-4(c) under the Exchange Act (17 CFR 240.13e-4(c))

Securities registered pursuant to Section 12(b) of the Act:


Title of each class	Trading Symbol	Name of each exchange on which registered
Common Stock, Par value $0.001 per share	PEN	The New York Stock Exchange

Indicate by check mark whether the registrant is an emerging growth company as defined in Rule 405 of the Securities Act of 1933 (§230.405 of this chapter) or Rule 12b-2 of the Securities Exchange Act of 1934 (§240.12b-2 of this chapter).

Emerging growth company ☐

If an emerging growth company, indicate by check mark if the registrant has elected not to use the extended transition period for complying with any new or revised financial accounting standards provided pursuant to Section 13(a) of the Exchange Act. o

_______________________________________________________________________________________________________________________________


Item 2.02.			Results of Operations and Financial Condition.

On July 30, 2026, Penumbra, Inc. issued a press release announcing financial results for the second fiscal quarter ended June 30, 2026. A copy of the press release is furnished as Exhibit 99.1 to this Current Report on Form 8-K and is incorporated herein by reference.

The information furnished on this Current Report on Form 8-K, including the attached exhibit, shall not be deemed “filed” for purposes of Section 18 of the Securities Exchange Act of 1934, as amended (the “Exchange Act”), or otherwise subject to the liabilities of that section, nor shall it be deemed incorporated by reference into any other filing under the Securities Act of 1933, as amended, or the Exchange Act, regardless of any general incorporation language in such a filing, except as expressly set forth by specific reference in such a filing.


Item 9.01.			Financial Statements and Exhibits.

(d) Exhibits.


Exhibit Number						Description
99.1						Press release of Penumbra, Inc. dated July 30, 2026.
104						Cover Page Interactive Data File (formatted as Inline Extensible Business Reporting Language).

SIGNATURES

Pursuant to the requirements of the Securities Exchange Act of 1934, the registrant has duly caused this report to be signed on its behalf by the undersigned hereunto duly authorized.


	Penumbra, Inc.

Date: July 30, 2026	By:	/s/ Maggie Yuen
		Maggie Yuen
		Chief Financial Officer

Exhibit 99.1

Penumbra, Inc. Reports Second Quarter 2026 Financial Results

ALAMEDA, Calif., July 30, 2026 /PRNewswire/ -- Penumbra, Inc. (NYSE: PEN), the world’s leading thrombectomy company, today reported financial results for the second quarter ended June 30, 2026.

•Revenue of $390.0 million in the second quarter of 2026, an increase of 14.9% compared to the second quarter of 2025.

•Global thrombectomy revenue of $259.0 million in the second quarter of 2026, an increase of 12.5% compared to the second quarter of 2025.

•Global embolization and access revenue of $131.1 million in the second quarter of 2026, an increase of 20.0% compared to the second quarter of 2025.

•Gross profit margin of 67.9% in the second quarter of 2026, an increase of 1.9% compared to the second quarter of 2025.

•Total operating expenses of $223.9 million in the second quarter of 2026, comprised of R&D of $25.4 million and SG&A of $198.5 million, which includes $6.9 million of acquisition-related expenses associated with the pending acquisition of Penumbra, Inc. by Boston Scientific Corporation.

•Income from operations of $41.0 million and net income of $34.8 million in the second quarter of 2026.

Full Year 2026 Financial Outlook and Webcast and Conference Call Information

Given the pending acquisition of Penumbra, Inc. by Boston Scientific Corporation (NYSE: BSX), the Company will not be providing financial guidance for the full year 2026 or hosting a conference call to discuss financial results for the three months ended June 30, 2026.

About Penumbra

Penumbra, Inc., the world’s leading thrombectomy company, is focused on developing the most innovative technologies for challenging medical conditions such as ischemic stroke, venous thromboembolism such as pulmonary embolism, and acute limb ischemia. Our broad portfolio, which includes computer assisted vacuum thrombectomy (CAVT), centers on removing blood clots from head-to-toe with speed, safety and simplicity. By pioneering these innovations, we support healthcare providers, hospitals and clinics in more than 100 countries, working to improve patient outcomes and quality of life. For more information, visit www.penumbrainc.com and connect on Instagram, LinkedIn, and X.

Forward-Looking Statements

Except for historical information, certain statements in this press release are forward-looking in nature and are subject to risks, uncertainties and assumptions about us. Our business and operations are subject to a variety of risks and uncertainties and, consequently, actual results may differ materially from those projected by any forward-looking statements. Factors that could cause actual results to differ from those projected include, but are not limited to: the risk that the pending acquisition by Boston Scientific Corporation will not be completed in the expected timeframe or at all, including the risk that required regulatory approvals will not be obtained; potential adverse effects to our business during the pendency of the acquisition, such as employee departures or diversion of management’s attention from our business; failure to sustain or grow profitability or generate positive cash flows; failure to effectively introduce and market new products; delays in product introductions; significant competition; inability to further penetrate our current customer base, expand our user base and increase the frequency of use of our products by our customers; inability to achieve or maintain satisfactory pricing and margins; manufacturing difficulties; permanent write-downs or write-offs of our inventory or other assets; product defects or failures; unfavorable outcomes in clinical trials; inability to maintain our culture as we grow; fluctuations in foreign currency exchange rates; potential adverse regulatory actions; and the potential impact of any acquisitions, mergers, dispositions, joint ventures or investments we may make. These risks and uncertainties, as well as others, are discussed in greater detail in our filings with the Securities and Exchange Commission ("SEC"), including our Annual Report on Form 10-K for the year ended December 31, 2025 filed with the SEC on February 25, 2026. There may be additional risks of which we are not presently aware or that we currently believe are immaterial which could have an adverse impact on our business. Any forward-looking statements are based on our current expectations, estimates and assumptions regarding future events and are applicable only as of the

dates of such statements. We make no commitment to revise or update any forward-looking statements in order to reflect events or circumstances that may change.

Penumbra, Inc.

Condensed Consolidated Balance Sheets

(unaudited)

(in thousands)


	June 30, 2026		December 31, 2025
Assets
Current assets:
Cash and cash equivalents	$	205,271	$	186,897
Marketable investments	453,524		357,919
Accounts receivable, net	190,407		190,021
Inventories	442,650		431,549
Prepaid expenses and other current assets	52,270		50,298

Total current assets	1,344,122		1,216,684
Property and equipment, net	146,718		117,436
Operating lease right-of-use assets	167,194		173,587
Finance lease right-of-use assets	24,357		25,972
Intangible assets, net	5,742		6,186
Goodwill	166,523		166,750

Deferred taxes	79,376		79,188
Other non-current assets	40,691		40,716
Total assets	$	1,974,723	$	1,826,519
Liabilities and Stockholders’ Equity
Current liabilities:
Accounts payable	$	44,728	$	34,736
Accrued liabilities	172,270		132,163
Current operating lease liabilities	14,398		13,841
Current finance lease liabilities	2,380		2,393
Total current liabilities	233,776		183,133

Non-current operating lease liabilities	176,304		182,751
Non-current finance lease liabilities	19,628		20,714
Other non-current liabilities	14,249		12,318
Total liabilities	443,957		398,916
Stockholders’ equity:
Common stock	39		39
Additional paid-in capital	1,224,278		1,185,525

Accumulated other comprehensive income	1,363		4,348
Retained earnings	305,086		237,691


Total stockholders’ equity	1,530,766		1,427,603
Total liabilities and stockholders’ equity	$	1,974,723	$	1,826,519

Penumbra, Inc.

Condensed Consolidated Statements of Operations

(unaudited)

(in thousands, except share and per share amounts)


	Three Months Ended June 30,				Six Months Ended June 30,
	2026		2025		2026		2025
Revenue	$	390,046	$	339,455	$	764,804	$	663,595
Cost of revenue	125,102		115,445		246,449		223,702
Gross profit	264,944		224,010		518,355		439,893
Operating expenses:
Research and development	25,396		23,218		47,778		45,295
Sales, general and administrative	198,509		159,964		391,304		313,420


Total operating expenses	223,905		183,182		439,082		358,715
Income from operations	41,039		40,828		79,273		81,178
Interest and other income, net	5,148		4,482		8,602		7,990


Income before income taxes	46,187		45,310		87,875		89,168
Provision for income taxes	11,376		40		20,480		4,675


Net income	$	34,811	$	45,270	$	67,395	$	84,493



Net income per share:
Basic	$	0.88	$	1.17	$	1.71	$	2.18
Diluted	$	0.88	$	1.15	$	1.70	$	2.15
Weighted average shares outstanding:
Basic	39,353,965		38,834,917		39,314,912		38,699,307
Diluted	39,572,059		39,245,953		39,572,347		39,214,027

Penumbra, Inc.

Reconciliation of Revenue Growth by Geographic Regions

(unaudited)

(in thousands, except for percentages)


	Three Months Ended June 30,				Change
	2026		2025		$		%
United States	$	305,445	$	260,818	$	44,627	17.1	%
International	84,601		78,637		5,964		7.6	%
Total	$	390,046	$	339,455	$	50,591	14.9	%


	Six Months Ended June 30,				Change
	2026		2025		$		%
United States	$	601,832	$	517,678	$	84,154	16.3	%
International	162,972		145,917		17,055		11.7	%
Total	$	764,804	$	663,595	$	101,209	15.3	%

Penumbra, Inc.

Reconciliation of Revenue Growth by Product Categories

(unaudited)

(in thousands, except for percentages)


	Three Months Ended June 30,				Change
	2026		2025		$		%
Thrombectomy	$	258,981	$	230,256	$	28,725	12.5	%
Embolization and Access	131,065		109,199		21,866		20.0	%
Total	$	390,046	$	339,455	$	50,591	14.9	%


	Six Months Ended June 30,				Change
	2026		2025		$		%
Thrombectomy	$	512,898	$	456,800	$	56,098	12.3	%
Embolization and Access	251,906		206,795		45,111		21.8	%
Total	$	764,804	$	663,595	$	101,209	15.3	%

Investor Relations

Penumbra, Inc.

[email protected]

Source: Penumbra, Inc.